Results 1 to 10 of about 7,378 (198)
Mesalamine Associated Bradycardia [PDF]
Cureus, 2018 A 38-year-old female presented with an acute flare of ulcerative colitis. She was started on prednisone and mesalamine. Within 24 hours of initiating mesalamine, she developed sinus bradycardia. After holding mesalamine, the heart rate returned to normal within five days.
Krzyzak, Michael +3 more
openaire +4 more sources
Oxidation of Mesalamine under Phenoloxidase- or Peroxidase-like Enzyme Catalysis
Molecules, 2023 Mesalamine, also called 5-ASA (5-aminosalicylic acid), is a largely used anti-inflammatory agent and is a main choice to treat Ulcerative Colitis. This report is aimed to investigate enzymatic processes involved in the oxidation of mesalamine to better ...
Rimaz El Zein +4 more
doaj +2 more sources
Case Reports in Gastroenterology, 2011 Mesalamine has been used as the first-line therapy for the treatment of ulcerative colitis (UC) because of its efficacy and fewer side effects. However, earlier study showed that mesalamine occasionally causes diarrhea.
Yuichi Shimodate +5 more
doaj +2 more sources
Cellular and Molecular Gastroenterology and Hepatology, 2017 Background & Aims: Mesalamine is a first-line drug for treatment of inflammatory bowel diseases (IBD). However, its mechanisms are not fully understood. CD4+ Foxp3+ regulatory T cells (Tregs) play a potential role in suppressing IBD.
Kyoko Oh-oka +11 more
doaj +2 more sources
Frontiers in Pharmacology, 2021 Mesalamine has been well used in the improvement of ulcerative colitis (UC) in clinics, however, the underlying mechanisms were not well illustrated. To explore its efficacy from the perspective of gut microbiota and related metabolites, we employed 16S ...
Liang Dai +8 more
doaj +1 more source
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study [PDF]
Intestinal Research, 2016 Background/AimsThe therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients.
Yasuo Suzuki +4 more
doaj +1 more source
Recent advances in mesalamine colonic delivery systems
Future Journal of Pharmaceutical Sciences, 2020 Background Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing ...
Mohammad F. Bayan, Rana F. Bayan
doaj +1 more source
Medicina, 2022 A 41-year-old man was treated with prednisolone (PSL) and multimatrix (MMX) mesalamine for remission induction therapy of ulcerative colitis. PSL was tapered due to successful remission induction treatment.
Mimari Kanazawa +9 more
doaj +1 more source
Gels, 2023 This research aims to develop a drug delivery system that effectively treats colitis while administering curcumin/mesalamine by coating alginate/chitosan beads with Eudragit® S-100 to target the colon. Beads were tested to determine their physicochemical
Eman J. Heikal +8 more
doaj +1 more source
Suppository treatment in ulcerative proctitis
European Journal of Inflammation, 2021 Ulcerative proctitis (UP) is a common form of ulcerative colitis (UC), the number of patients with UP is increasing. Suppository treatment containing mesalamine is usually the first-line choice for mild to moderate UP, here, we review the publications on
Yingjie Si +3 more
doaj +1 more source